Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial
Aesthetic Plastic Surgery · 2025
DOI: 10.1007/s00266-025-04929-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Plastic Surgery, 2025. Verfasst von Ghazal Ghochani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oculofacial Plastic and Reconstructive Surgery, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Neuromuscular Agents. Die Arbeit nennt 24 Literaturangaben. Gefördert von: MasoonDarou Pharmaceutical Company, Tehran, Iran.
Abstract (Originalsprache)
BACKGROUND: Botulinum neurotoxin type A has played a key role in the treatment of facial rhytides. We aimed to compare the safety and effectiveness of Masport and Dysport as botulinum toxin type A preparations in the treatment of upper face rhytides. METHODS: A double-blind randomized, clinical trial was conducted on adults with at least mild severity (scale 1) for lateral canthal (crow's feet), glabellar, and frontal lines at maximum contraction positions (dynamic status), regardless of their static scales (rest position). Participants were randomly assigned to receive either Masport or Dysport. Rhytides in each area were scaled at baseline and at post-injection weeks 2, 8, 12, and 16. Self-satisfaction were assessed at follow-ups. RESULTS: For both groups, a decrease in dynamic rhytides was observed at week 2 compared to baseline (all Ps 0.05). While at week 2, both dynamic and static scales were higher in the Masport group (all Ps 0.05). CONCLUSION: The onset and duration of action for Masport and Dysport are similar in the treatment of upper face rhytides at equal doses. While Dysport may initially show a stronger effect than Masport in treating upper face rhytides, this advantage does not persist in the long term. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oculofacial Plastic and Reconstructive Surgery, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Oculofacial Plastic and Reconstructive Surgery, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. mohsen_raf1354@yahoo.com.
Förderung
- MasoonDarou Pharmaceutical Company, Tehran, Iran
Zitieren
APA
Ghochani, G., Aghajani, A., Rajabi, M. T., Zand, A., Yaseri, M., & Rafizadeh, S. M. (2025). Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial. Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-025-04929-2
Vancouver
Ghochani G, Aghajani A, Rajabi MT, Zand A, Yaseri M, Rafizadeh SM. Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial. Aesthetic Plastic Surgery. 2025. doi:10.1007/s00266-025-04929-2
BibTeX
@article{Ghochani2025,
author = {Ghochani, Ghazal and Aghajani, Amirhossein and Rajabi, Mohammad Taher and Zand, Amin and Yaseri, Mehdi and Rafizadeh, Seyed Mohsen},
title = {Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial},
journal = {Aesthetic Plastic Surgery},
year = {2025},
doi = {10.1007/s00266-025-04929-2}
}
EUVIMED